Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | SRC | P12931 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 6/20 | 0.50 |
| ▸ | HCK | P08631 | 5/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.50 |
| ▸ | MTOR | P42345 | 4/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.50 |
| ▸ | PRKDC | P78527 | 4/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.50 |
| ▸ | BTK | Q06187 | 12/20 | 0.44 |
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.44 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.44 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682621 | 0.90 | SRC (0.50) | EGFRSRCABL1HCKPIK3CD | |
| SCHEMBL1614407 | 0.90 | SRC (0.49) | EGFRSRCABL1HCKPIK3CD | |
| SCHEMBL17375372 | 0.77 | BTK (0.53) | EGFRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL16078942 | 0.72 | BTK (0.53) | EGFRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL28747962 | 0.71 | NUDT14 (0.61) | EGFRSRCABL1HCKPIK3CD | |
| SCHEMBL27586498 | 0.71 | NUDT14 (0.58) | EGFRSRCABL1HCKPIK3CD | |
| SCHEMBL1613478 | 0.70 | BTK (0.51) | EGFRSRCABL1HCKBTK | |
| SCHEMBL1613484 | 0.70 | BTK (0.51) | EGFRSRCABL1HCKBTK | |
| SCHEMBL1613481 | 0.70 | BTK (0.51) | EGFRSRCABL1HCKBTK | |
| SCHEMBL19176242 | 0.69 | NUDT14 (0.58) | EGFRSRCABL1HCKPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2393816-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 947/4885SRC 11/4885ABL1 1/4885 |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 947/4885SRC 11/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.